Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long-term data ...
Discounts on Okami HD, Dragon's Crown, Need for Speed Rivals, LEGO Marvel Super Heroes, Ys: Memories of Celceta, Tomb Raider - Definitive Edition, Thief and more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback